trastuzumab deruxtecan,ruxolitinib
novartis,daiichi sankyo,incyte,astrazeneca
['gynca', 'gyn', 'trastuzumab deruxtecan', 'rux,(-crux),(-trux)', 'bladder', 'solid tumor', 'pantumor', 'destiny,pantumor02']
trastuzumab deruxtecan in her2+ in solid tumors amazing responses in cervical, uterine, ovary, bladder destiny-pantumor02
orr: 50% (cervix), 57% (uterus), 45% (ov)
cr: 5% (cervix), 17.5% (uterus), 10% (ov)
mdor: 9.8 mo (cervix), nr (uterus), 11.3 mo (ov) #asco23 #gyncancer 
Med Oncologist, GYN Women’s Cancer, #YaleCancer, #YaleMedicine, #SmilowCancer